MX365886B - Combinación de reguladores metabólicos bioenergéticos y nutra-epigenéticos, compuestos nutracéuticos en combinaciones convencionales y nanotecnológicas para revertir y prevenir la senescencia celular acelerada por daño crónico producida por diabetes y otras enfermedades complejas crónico-degenerativas. - Google Patents
Combinación de reguladores metabólicos bioenergéticos y nutra-epigenéticos, compuestos nutracéuticos en combinaciones convencionales y nanotecnológicas para revertir y prevenir la senescencia celular acelerada por daño crónico producida por diabetes y otras enfermedades complejas crónico-degenerativas.Info
- Publication number
- MX365886B MX365886B MX2017007448A MX2017007448A MX365886B MX 365886 B MX365886 B MX 365886B MX 2017007448 A MX2017007448 A MX 2017007448A MX 2017007448 A MX2017007448 A MX 2017007448A MX 365886 B MX365886 B MX 365886B
- Authority
- MX
- Mexico
- Prior art keywords
- combination
- chronic
- diabetes
- epigentic
- nutra
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000002715 bioenergetic effect Effects 0.000 title 1
- 230000009693 chronic damage Effects 0.000 title 1
- 230000001684 chronic effect Effects 0.000 title 1
- 230000003412 degenerative effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 230000002503 metabolic effect Effects 0.000 title 1
- 235000021436 nutraceutical agent Nutrition 0.000 title 1
- 230000009758 senescence Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
- 201000005569 Gout Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000001280 Prediabetic State Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 210000000577 adipose tissue Anatomy 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 201000010064 diabetes insipidus Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 1
- 229940116269 uric acid Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La invención se refiere a compuestos de origen natural y su mezcla farmacéuticamente aceptable y activa para disminuir los altos niveles de glucosa, colesterol, ácido úrico y grasa corporal, citoprotección de órganos dañados, activación del metabolismo y la proliferación celular. Se ejemplifica con la composición farmacéutica que comprende una cantidad farmacéuticamente eficaz de los compuestos de la Formulación I, y su método en sistemas in vitro e in vivo. La Formulación I y sus variables pueden usarse para tratar hiperglucemia, gota, dislipidemia, obesidad, resistencia a la insulina, diabetes mellitus, diabetes insípida, diabetes tipo 1, diabetes tipo 2, complicaciones microvasculares, complicaciones macrovasculares, trastornos lipídicos, prediabetes, arritmias, infarto de miocardio, complicaciones renales y pancreáticas, complicaciones cardiovasculares.
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019517750A JP2019521184A (ja) | 2015-06-08 | 2017-06-08 | 糖尿病および他の変性慢性複合疾患によって生じる慢性損傷促進性細胞老化を元の状態に戻すおよび予防するための、代謝バイオエネルギー調節因子とニュートラエピジェネティック調節因子の組合せ、従来技術とナノテクノロジーを組み合わせた栄養補助化合物 |
| CN201780046806.6A CN109890369B (zh) | 2015-06-08 | 2017-06-08 | 用于预防和减轻由糖尿病引起的慢性损伤的严重性的代谢调节剂和化合物的组合 |
| RU2018147077A RU2749950C2 (ru) | 2015-06-08 | 2017-06-08 | Применение композиции, состоящей из аминокислот глицина, аргинина, цистеина и ресвератрола, для снижения тяжести диабета и высокого содержания жира в организме, холестерина, мочевой кислоты, глюкозы в крови и ускоренного старения у животных и человека |
| CA3027048A CA3027048A1 (en) | 2015-06-08 | 2017-06-08 | Combination of metabolic regulators and nutraceuticals for the prevention of chronic damage from diabetes |
| PCT/MX2017/000061 WO2017213486A2 (es) | 2016-06-08 | 2017-06-08 | Combinación de reguladores metabólicos bioenergéticos y nutra-epigenéticos, compuestos nutracéuticos en combinaciónes convencionales y nanotecnológicas para revertir y prevenir la sesencencia celular acelerada por daño crónico producida por diabetes y otras enfermedades complejas crónico-degenerativas |
| BR112018075395-5A BR112018075395A2 (pt) | 2015-06-08 | 2017-06-08 | combinação de reguladores metabólicos bioenergé-ticos e nutra-epigenéticos, compostos nutracêuti-cos em combinações convencionais e baseadas em na-notecnologia para reverter e prevenir a senescên-cia celular acelerada por lesão crônica causada por diabetes e outras doenças complexas crônico-degenerativas |
| EP17810608.4A EP3470060B1 (en) | 2016-06-08 | 2017-06-08 | Composition comprising resveratrol, glycine, arginine and cysteine for use in treating metabolic syndrome |
| CL2018003531A CL2018003531A1 (es) | 2016-06-08 | 2018-12-07 | Combinación de reguladores metabólicos bioenergéticos y nutra-epigenéticos, compuestos nutracéuticos en combinaciones convencionales y nanotecnológicas para revertir y prevenir la senescencia celular acelerada por daño crónico producida por diabetes y otras enfermedades complejas crónico-degenerativas. |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562172339P | 2015-06-08 | 2015-06-08 | |
| US15/176,422 US10285963B2 (en) | 2015-06-08 | 2016-06-08 | Combination of metabolic bio-energetic and nutra-epigentic regulators, nutraceutical compounds in conventional and nanotechnologies combination to revert and prevent the chronic damage accelerated cellular senescence produced by diabetes and other degenerative chronic complex diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017007448A MX2017007448A (es) | 2018-09-10 |
| MX365886B true MX365886B (es) | 2019-06-19 |
Family
ID=57450744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017007448A MX365886B (es) | 2015-06-08 | 2017-06-07 | Combinación de reguladores metabólicos bioenergéticos y nutra-epigenéticos, compuestos nutracéuticos en combinaciones convencionales y nanotecnológicas para revertir y prevenir la senescencia celular acelerada por daño crónico producida por diabetes y otras enfermedades complejas crónico-degenerativas. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10285963B2 (es) |
| JP (1) | JP2019521184A (es) |
| CN (1) | CN109890369B (es) |
| BR (1) | BR112018075395A2 (es) |
| CA (1) | CA3027048A1 (es) |
| MX (1) | MX365886B (es) |
| RU (1) | RU2749950C2 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017213486A2 (es) * | 2016-06-08 | 2017-12-14 | Astudillo De La Vega Horacio | Combinación de reguladores metabólicos bioenergéticos y nutra-epigenéticos, compuestos nutracéuticos en combinaciónes convencionales y nanotecnológicas para revertir y prevenir la sesencencia celular acelerada por daño crónico producida por diabetes y otras enfermedades complejas crónico-degenerativas |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006273834A (ja) * | 2004-06-28 | 2006-10-12 | Kao Corp | Ａｍｐｋ活性化剤 |
| US7709539B2 (en) * | 2004-08-11 | 2010-05-04 | Chang Gung University | Therapeutic use of resveratrol for hyperglycemia |
| ITPD20050224A1 (it) * | 2005-07-19 | 2007-01-20 | Actimex Srl | Composizioni contenenti micronutrienti aventi in particolare attivita' antiossidante e loro impiego |
| US20100209382A1 (en) * | 2005-09-16 | 2010-08-19 | Ordway Research Institute, Inc. | Polyphenol Conjugates as RGD-Binding Compounds and Methods of Use |
| WO2008143182A1 (ja) * | 2007-05-17 | 2008-11-27 | Kaneka Corporation | 甘草ポリフェノールを含有する組成物 |
| JP5594819B2 (ja) * | 2009-12-22 | 2014-09-24 | キリンホールディングス株式会社 | 脂質代謝改善用組成物 |
| JP2012041296A (ja) * | 2010-08-19 | 2012-03-01 | Medience Corp | 血管内皮機能改善剤、一酸化窒素産生促進剤、及び飲食品 |
| WO2013012760A1 (en) * | 2011-07-15 | 2013-01-24 | Numeta Sciences, Inc. | Compositions and methods for modulating metabolic pathways |
-
2016
- 2016-06-08 US US15/176,422 patent/US10285963B2/en active Active
-
2017
- 2017-06-07 MX MX2017007448A patent/MX365886B/es active IP Right Grant
- 2017-06-08 CA CA3027048A patent/CA3027048A1/en active Pending
- 2017-06-08 JP JP2019517750A patent/JP2019521184A/ja active Pending
- 2017-06-08 CN CN201780046806.6A patent/CN109890369B/zh active Active
- 2017-06-08 RU RU2018147077A patent/RU2749950C2/ru active
- 2017-06-08 BR BR112018075395-5A patent/BR112018075395A2/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019521184A (ja) | 2019-07-25 |
| RU2018147077A3 (es) | 2020-09-21 |
| BR112018075395A2 (pt) | 2019-04-02 |
| RU2749950C2 (ru) | 2021-06-21 |
| RU2018147077A (ru) | 2020-07-10 |
| US20160354331A1 (en) | 2016-12-08 |
| CN109890369B (zh) | 2022-04-29 |
| MX2017007448A (es) | 2018-09-10 |
| CN109890369A (zh) | 2019-06-14 |
| CA3027048A1 (en) | 2017-12-14 |
| US10285963B2 (en) | 2019-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Börgeson et al. | Lipoxin A4 attenuates obesity-induced adipose inflammation and associated liver and kidney disease | |
| PH12018500767A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
| PH12018501424B1 (en) | A composition for treating diabetes or diabesity comprising oxyntomodulin analog | |
| NZ743706A (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| MY176863A (en) | Ibat inhibitors for treatment of metabolic disorders and related conditions | |
| WO2011057249A3 (en) | Treatment of heart disease | |
| SV2009003146A (es) | Moduladores del metabolismo y tratamiento de los transtornos metabolicos ref. 20750-0033sv1 (137. sv1.pct) | |
| NO20090590L (no) | Metabolisme modulatorer samt behandling av lidelser relatert dertil | |
| WO2011153542A3 (en) | Regulation of metabolism by mir-378 | |
| WO2011057251A3 (en) | Treatment of heart disease | |
| WO2010129138A3 (en) | Phosphorylated and phosphonated pyrone analogs for therapeutic treatment | |
| CAI | The oxidative stress and diabetic complications | |
| MX365886B (es) | Combinación de reguladores metabólicos bioenergéticos y nutra-epigenéticos, compuestos nutracéuticos en combinaciones convencionales y nanotecnológicas para revertir y prevenir la senescencia celular acelerada por daño crónico producida por diabetes y otras enfermedades complejas crónico-degenerativas. | |
| WO2013078376A3 (en) | Isoxazole treatments for diabetes | |
| Kamble et al. | Cardioprotective effect of concomitant administration of trigonelline and sitagliptin on cardiac biomarkers, lipid levels, electrocardiographic and heamodynamic modulation on cardiomyopathy in diabetic Wistar rats | |
| Ametov et al. | Oxidative stress in type 2 diabetes mellitus and methods for its correction | |
| Huang et al. | Carvedilol improved diabetic rat cardiac function depending on antioxidant ability | |
| WO2010108051A3 (en) | Inhibitors of diacylglycerol o-acyltransferase 1(dgat-1) and uses thereof | |
| WO2017213486A3 (es) | Combinación de reguladores metabólicos bioenergéticos y nutra-epigenéticos, compuestos nutracéuticos en combinaciónes convencionales y nanotecnológicas para revertir y prevenir la sesencencia celular acelerada por daño crónico producida por diabetes y otras enfermedades complejas crónico-degenerativas | |
| WO2013033165A3 (en) | Compositions, kits and methods for treating obesity, diabetes and hyperglycemia | |
| WO2011090265A3 (ko) | 신코닌을 유효성분으로 포함하는 비만, 이상지방혈증, 지방간 또는 인슐린 저항성 증후군의 예방 또는 치료용 조성물 | |
| Rivera et al. | 8-hydroxy-2'-deoxyguanosine and lipid peroxidation in patients with heart failure | |
| WO2014014819A3 (en) | Methods of treating glucose metabolism disorders | |
| WO2012154009A3 (ko) | 티에노피리미딘 유도체， 이의 약학적으로 허용가능한 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨 관련 질환의 또는 치료용 약학적 조성물 | |
| Ganda | Comment on Jakubowicz et al. Fasting Until Noon Triggers Increased Postprandial Hyperglycemia and Impaired Insulin Response After Lunch and Dinner in Individuals With Type 2 Diabetes: A Randomized Clinical Trial. Diabetes Care 2015; 38: 1820–1826 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |